A Phase 1/2 interventional study of Dexmedetomidine and Placebo in Opioid Withdrawal, sponsored by BioXcel Therapeutics Inc. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by BioXcel Therapeutics Inc · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,222 studies in Opioid-Related Disorders with a site in United States — 245 open to participants now, 315 under way, 18 of them phase 3. Opioid-Related Disorders · United States.
Among the 1,222 studies in Opioid-Related Disorders with a site in United States, this one is the 227th largest by enrollment of the 1,097 interventional ones that give a count, is one of 94 that started in 2020, is one of 30 in phase 1/2, and was the 671st registered.
1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
Browse Opioid-Related Disorders studies →245 of the 1,222 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:
Washington State University · Sites in United States
Ages 18+
University of Massachusetts, Worcester · Sites in United States
Ages 18+ · Healthy volunteers
Baylor College of Medicine · Sites in United States
Ages 18–64
Yale University · Sites in United States
Ages 25–65 · Healthy volunteers
Adneuris Therapeutics, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,222 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 162 · Phase 2 245 · Phase 3 99 · Phase 4 79
First in 1988; this study’s year is marked. 94 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 225 is above the median of 63 across 1,167 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 56 across the 1,097 interventional studies, 85 across the 122 observational. Of the 834 that completed or were terminated, 331 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 1,222 have an industry lead sponsor. The 10 most frequent:
BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
BioXcel Therapeutics Inc has 1 study filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
128 of the studies in Opioid-Related Disorders with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05011266Phase 3New York State Psychiatric InstituteEfficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder | 2027-01-01 |
| NCT05834478Phase 3Emory UniversityNon-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 | 2027-02 |
| NCT05033028Phase 3NYU Langone HealthSmartphones for Opiate Addiction Recovery | 2027-06-01 |
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT05766631Phase 3Friends Research Institute, Inc.Treating Polysubstance Use Using a Novel Digital Technology | 2027-06-30 |
Add all 128 to your calendar (.ics) → With an account.
Among the 1,222 studies in Opioid-Related Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance. The opioid (morphine) maintenance phase (Phase 1b) included Days 1-5; the randomized BXCL501/placebo phase (Phase 2) included Days 6-12. The randomized phase was followed by 2 sequential days, Days 13 and 14, utilizing treatment of BXCL501-placebo sublingual films and morphine-placebo capsules for all subjects who remained in the study.
This Study included two phases, Phase 1b and Phase 2. Phase 1b was the morphine maintenance phase, Days 1 through 5 and Phase 2 was the randomized, double-blind, placebo-controlled, ascending-dose study of BXCL501 sublingual films on Days 6-12 to treat symptoms of acute opioid withdrawal in patients with opioid use disorder who are/were physically dependent on opioids. Day 12 was followed by 2 sequential days (Days 13 and 14) of BXCL501 vs. placebo and morphine vs. placebo treatment for all subjects who remained in the study.
After a 30-day screening period, eligible male and female adult subjects with Opioid Use Disorder (OID) who were physically dependent on opioids and were not seeking treatment for opioid withdrawal symptoms were admitted to an inpatient unit. The opioid maintenance phase of the study (Phase 1b, Days 1-5) began on Day 1 and continued through Day 5. Approximately 225 subjects were enrolled in the Phase 1b study in cohorts (approximately 25 subjects/cohort). All subjects enrolled in the Phase 1b portion of the study received oral morphine capsules. The total dose of morphine during the opioid maintenance phase varied at the discretion of the investigator, ranged between 120 mg and 150 mg per day, depending on patients abuse history and need for higher dose to stabilize withdrawal symptoms. In addition, these subjects received placebo sublingual films approximately 12 hours apart to simulate and thus blind treatment of BXCL501 during Phase 2 of the study (Days 6-12).
Abrupt discontinuation of active morphine began on Day 6 (Phase 2) and subjects were randomized in a 4:1 ratio to receive either BXCL501 sublingual films or placebo sublingual films, respectively. 135 subjects enrolled/rolled over from the Phase 1b portion of the study into the randomized, double-blind, placebo-controlled portion of the study (Phase 2). Subjects were treated according to their assigned, randomized treatment from Day 6 through Day 12. Treatment was administered approximately 12 hours apart at approximately 8am (±30 minutes) and 8pm (±30 minutes); the 2nd dose (evening dose) was administered only to subjects that were hemodynamically stable, not hypotensive (must be greater than 110/70 diastolic/systolic), and not bradycardic (must be greater than 55 beats per minute (bpm)). Subjects were not given the second dose if they were orthostatic (a drop of 20 points in either systolic blood pressure (SBP) or 10 points in Diastolic Blood Pressure (DBP)) or if they were experiencing an Adverse Event (AE) that when assessed by the Investigator. If a subject experienced SBP \<90 mmHg; or DBT \<60 millimeters of mercury (mmHg); or Heart Rate (HR) \<50 bpm, immediately prior to the next dose, administration of the study medication for that subject was withheld until resolution of the BP and HR parameters. The administration hold did not exceed 2 hours. Safety and tolerability were monitored continuously and summarized upon completion of each cohort by medical safety review.
Studies of opioid withdrawal with placebo arms are likely to have high dropout rates, thus, the dropouts prior to Day 6 could be replaced to ensure enough sample size entering the treatment phase in Phase 2. Dropouts after Day 6 were not to be replaced. The study was intended to be flexible and adaptable, and as such, the dosing frequency, the doses, and the number of cohorts of BXCL501 allowed for change based on ongoing safety review and medical monitoring of safety, tolerability, and efficacy data after each dose-escalating cohort.
Phase 2 evaluated 6 cohorts (n=25 subjects per cohort according to the 4:1 randomization ratio; n= 20 active BXCL501 and n=5 placebo). The following doses were administered: 30 µg (Cohort 1), 60 µg (Cohort 2), 90 µg (Cohort 3), 120 µg (Cohort 4), and 180 µg (Cohort 5). The dose for Cohort 6 (240 μg) was determined from data acquired from Cohorts 1-5 and Cohort 6 was activated prior to the end of the study.
Other evaluations during the study included establishing the preliminary efficacy of multiple BXCL501 doses relative to placebo and evaluation of pharmacokinetics (PK) in subjects undergoing opiate withdrawal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sublingual film containing 30 Micrograms Dexmedetomidine or Placebo Sublingual film
Drug: Dexmedetomidine · Drug: Placebo
Sublingual film containing 60 Micrograms Dexmedetomidine or Placebo Sublingual film
Drug: Dexmedetomidine · Drug: Placebo
Sublingual film containing 90 Micrograms Dexmedetomidine or Placebo Sublingual film
Drug: Dexmedetomidine · Drug: Placebo
Sublingual film containing 120 Micrograms Dexmedetomidine or Placebo Sublingual film
Drug: Dexmedetomidine · Drug: Placebo
Sublingual film containing 180 Micrograms Dexmedetomidine or Placebo Sublingual film
Drug: Dexmedetomidine · Drug: Placebo
Sublingual film containing 240 Micrograms Dexmedetomidine or Placebo Sublingual film
Drug: Dexmedetomidine · Drug: Placebo
Sublingual Film of Dexmedetomidine
Also known as: BXCL501
Sublingual Placebo film
Also known as: Placebo comparator
Peak SOWS Scores at Baseline and Over Time
Short Opiate Withdrawal Scale (SOWS)-Gossop: The SOWs scale is a validated 10-item patient-reported scale designed to measure the symptoms of withdrawal in subjects who are dependent on opioids. Each of the 10 items represents a symptom: "feeling sick," "stomach cramps," "muscle spasms/twitching," "feeling of coldness," "heart pounding," "muscular tension," "aches and pains," "yawning," "runny eyes," and "insomnia/problems sleeping." Scores on the SOWS-Gossop can range from 0 to 30, with higher scores indicating greater severity of withdrawal symptoms.
Time frame: Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose
Peak COWS Score at Baseline and Over Time
Clinical Opiate Withdrawal Scale (COWS): The COWS scale is a validated, 11-item questionnaire designed to quantify withdrawal symptoms. Symptoms evaluated include resting pulse rate, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh. COWS total scores range from 0 to 48, with 5 to 12 indicating mild symptoms, 13 to 24 indicating moderate symptoms, 25 to 36 indicating moderately severe symptoms, and greater than 36 indicating severe symptoms.
Time frame: Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose
Average COWS Scores at Baseline and Over Time
Clinical Opiate Withdrawal Scale (COWS): The COWs scale is a validated, 11-item questionnaire designed to quantify withdrawal symptoms. Symptoms evaluated include resting pulse rate, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh. COWS total scores range from 0 to 48, with 5 to 12 indicating mild symptoms, 13 to 24 indicating moderate symptoms, 25 to 36 indicating moderately severe symptoms, and greater than 36 indicating severe symptoms.
Time frame: Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose
Average SOWS at Baseline and Over Time
Short Opiate Withdrawal Scale (SOWS)-Gossop: The SOWs scale is a validated 10-item patient-reported scale designed to measure the symptoms of withdrawal in subjects who are dependent on opioids.5 Each of the 10 items represents a symptom: "feeling sick," "stomach cramps," "muscle spasms/twitching," "feeling of coldness," "heart pounding," "muscular tension," "aches and pains," "yawning," "runny eyes," and "insomnia/problems sleeping." Scores on the SOWS-Gossop can range from 0 to 30, with higher scores indicating greater severity of withdrawal symptoms.
Time frame: Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose
Time to Drop-out After Discontinuation of Opioid Maintenance Phase
Time to drop-out during double-blind treatment phase after discontinuation of opioid maintenance Phase.
Time frame: Day 6 through Day 14
Number and Percentage of Subject Drop-out After Discontinuation of Opioid Maintenance Phase Maintenance Within Each Treatment Group
Number and Percentage of Subject Drop-out after Discontinuation of Opioid Maintenance Phase Within Each Treatment Group Between Days 6-14.
Time frame: Day 6 through Day 14
Total ACES Total Score Over Time - 2 hr. Post-First Dose
Overall Agitation-Calmness Evaluation Scale (ACES): The ACES scale is a single-item measure rating overall agitation and sedation, ranging from 1 (marked agitation) to 9 (unarousable). This outcome measures the total ACES total score over time at 2 hours, post-first dose.
Time frame: Post-Dose Day 6 to Day 12
| Milestone | Morphine Maintenance, Then Cohort 1- 30 Micrograms | Morphine Maintenance, Then Cohort 2- 60 Micrograms | Morphine Maintenance, Then Cohort 3- 90 Micrograms | Morphine Maintenance, Then Cohort 4- 120 Micrograms | Morphine Maintenance, Then Cohort 5- 180 Micrograms | Morphine Maintenance, Then Cohort 6- 240 Micrograms | Morphine Maintenance, Then Cohort 7- Placebo |
|---|---|---|---|---|---|---|---|
| Started | 29 | 35 | 31 | 32 | 40 | 33 | 25 |
| Completed | 17 | 17 | 21 | 19 | 21 | 15 | 25 |
| Not completed | 12 | 18 | 10 | 13 | 19 | 18 | 0 |
| Milestone | Morphine Maintenance, Then Cohort 1- 30 Micrograms | Morphine Maintenance, Then Cohort 2- 60 Micrograms | Morphine Maintenance, Then Cohort 3- 90 Micrograms | Morphine Maintenance, Then Cohort 4- 120 Micrograms | Morphine Maintenance, Then Cohort 5- 180 Micrograms | Morphine Maintenance, Then Cohort 6- 240 Micrograms | Morphine Maintenance, Then Cohort 7- Placebo |
|---|---|---|---|---|---|---|---|
| Started | 17 | 17 | 21 | 19 | 21 | 15 | 25 |
| Completed | 7 | 5 | 6 | 7 | 5 | 6 | 6 |
| Not completed | 10 | 12 | 15 | 12 | 16 | 9 | 19 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 10 | 12 | 15 | 11 | 15 | 9 | 19 |
Short Opiate Withdrawal Scale (SOWS)-Gossop: The SOWs scale is a validated 10-item patient-reported scale designed to measure the symptoms of withdrawal in subjects who are dependent on opioids. Each of the 10 items represents a symptom: "feeling sick," "stomach cramps," "muscle spasms/twitching," "feeling of coldness," "heart pounding," "muscular tension," "aches and pains," "yawning," "runny eyes," and "insomnia/problems sleeping." Scores on the SOWS-Gossop can range from 0 to 30, with higher scores indicating greater severity of withdrawal symptoms.
| score on a scale | 30 Micrograms | 60 Micrograms | 90 Micrograms | 120 Micrograms | 180 Micrograms | 240 Micrograms | Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Baseline, Pre-Dose, Day 6 | 3.6 ± 3.24 | 5.2 ± 3.86 | 6.0 ± 5.45 | 4.7 ± 4.64 | 5.0 ± 4.43 | 6.5 ± 7.38 | 6.2 ± 6.93 |
| Day 6 Post-dose | 4.0 ± 3.30 | 9.1 ± 7.49 | 7.7 ± 5.01 | 8.6 ± 7.05 | 9.0 ± 7.20 | 11.2 ± 6.27 | 7.5 ± 7.08 |
| Day 7 Post-dose | 8.8 ± 8.19 | 9.6 ± 7.09 | 9.3 ± 6.10 | 10.7 ± 7.20 | 14.9 ± 9.42 | 14.2 ± 11.17 | 10.2 ± 8.10 |
| Day 8 Post-dose | 9.8 ± 7.86 | 7.4 ± 7.23 | 8.6 ± 5.86 | 8.0 ± 6.46 | 10.8 ± 7.63 | 12.0 ± 7.59 | 9.1 ± 7.50 |
| Day 9 Post-dose | 6.8 ± 3.35 | 6.0 ± 3.27 | 6.5 ± 4.72 | 6.9 ± 6.44 | 10.2 ± 6.44 | 11.5 ± 9.27 | 8.0 ± 9.74 |
| Day 10 Post-dose | 6.7 ± 6.02 | 4.3 ± 2.66 | 5.3 ± 5.28 | 4.6 ± 5.87 | 8.5 ± 5.22 | 8.5 ± 5.32 | 4.1 ± 3.80 |
| Day 11 Post-dose | 4.0 ± 3.96 | 3.8 ± 4.38 | 3.4 ± 3.64 | 2.5 ± 2.56 | 7.2 ± 6.34 | 4.8 ± 3.25 | 5.1 ± 8.57 |
| Day 12 Post-dose | 5.4 ± 5.65 | 3.2 ± 3.03 | 2.8 ± 3.54 | 2.9 ± 3.83 | 5.7 ± 5.10 | 5.2 ± 3.76 | 7.0 ± 11.38 |
| Day 13 Post-dose | 5.0 ± 4.12 | 5.4 ± 6.99 | 4.0 ± 3.90 | 4.0 ± 4.57 | 3.3 ± 2.29 | 3.5 ± 1.38 | 4.3 ± 6.22 |
| Day 14 Post-dose | 2.4 ± 2.64 | 2.8 ± 3.83 | 2.7 ± 3.88 | 2.1 ± 2.54 | 1.7 ± 2.34 | 1.2 ± 1.83 | 4.3 ± 9.67 |
Clinical Opiate Withdrawal Scale (COWS): The COWS scale is a validated, 11-item questionnaire designed to quantify withdrawal symptoms. Symptoms evaluated include resting pulse rate, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh. COWS total scores range from 0 to 48, with 5 to 12 indicating mild symptoms, 13 to 24 indicating moderate symptoms, 25 to 36 indicating moderately severe symptoms, and greater than 36 indicating severe symptoms.
| score on a scale | 30 Micrograms | 60 Micrograms | 90 Micrograms | 120 Micrograms | 180 Micrograms | 240 Micrograms | Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Baseline (Pre-Dose, Day 6) | 2.4 ± 1.77 | 4.6 ± 3.54 | 5.2 ± 3.87 | 4.1 ± 2.68 | 4.4 ± 3.07 | 3.8 ± 2.76 | 2.7 ± 2.49 |
| Day 6 Post dose | 4.2 ± 2.77 | 6.7 ± 3.16 | 4.6 ± 2.28 | 4.1 ± 2.56 | 5.4 ± 3.17 | 6.7 ± 3.83 | 5 ± 2.83 |
| Day 7 Postdose | 8.8 ± 5.37 | 6.1 ± 3.73 | 6.1 ± 2.32 | 6.5 ± 3.07 | 7.4 ± 3.65 | 7.3 ± 4.29 | 6.1 ± 3.25 |
| Day 8 Postdose | 8.9 ± 5.54 | 4.3 ± 3.4 | 6.1 ± 3.93 | 4.8 ± 2.86 | 6.8 ± 3.64 | 6.0 ± 4.29 | 5.9 ± 3.61 |
| Day 9 Postdose | 6.2 ± 3.80 | 4.7 ± 1.98 | 4.7 ± 2.54 | 3.5 ± 2.22 | 7.0 ± 3.30 | 6.8 ± 3.01 | 6.0 ± 6.14 |
| Day 10 Postdose | 4.9 ± 3.67 | 3.5 ± 1.52 | 3.7 ± 2.56 | 3.5 ± 2.07 | 4.6 ± 1.91 | 3.8 ± 1.47 | 3.9 ± 2.17 |
| Day 11 Postdose | 5.4 ± 4.28 | 5.0 ± 5.83 | 2.0 ± 1.63 | 3.4 ± 2.20 | 4.5 ± 3.33 | 3.5 ± 2.26 | 3.0 ± 2.83 |
| Day 12 Postdose | 3.6 ± 2.07 | 4.6 ± 4.28 | 2.0 ± 1.10 | 2.4 ± 1.77 | 3.6 ± 2.46 | 3.3 ± 1.75 | 4.5 ± 4.76 |
| Day 13 Postdose | 5.3 ± 2.93 | 4.0 ± 3.67 | 4.2 ± 2.93 | 2.5 ± 1.77 | 2.6 ± 1.27 | 3.0 ± 2.10 | 3.2 ± 3.97 |
| Day 14 Postdose | 3.4 ± 1.99 | 3.2 ± 2.17 | 2.8 ± 2.32 | 1.4 ± 1.62 | 2.3 ± 1.37 | 3.3 ± 2.42 | 3.5 ± 3.56 |
Clinical Opiate Withdrawal Scale (COWS): The COWs scale is a validated, 11-item questionnaire designed to quantify withdrawal symptoms. Symptoms evaluated include resting pulse rate, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh. COWS total scores range from 0 to 48, with 5 to 12 indicating mild symptoms, 13 to 24 indicating moderate symptoms, 25 to 36 indicating moderately severe symptoms, and greater than 36 indicating severe symptoms.
| score on a scale | 30 Micrograms | 60 Micrograms | 90 Micrograms | 120 Micrograms | 180 Micrograms | 240 Micrograms | Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Baseline (Pre-Dose, Day 6) | 2.41 ± 1.770 | 4.59 ± 3.537 | 5.19 ± 3.868 | 4.05 ± 2.677 | 4.38 ± 3.074 | 3.80 ± 2.757 | 2.71 ± 2.493 |
| Day 6, Post-Dose | 3.21 ± 1.913 | 5.22 ± 3.173 | 3.85 ± 2.254 | 3.26 ± 2.287 | 4.29 ± 2.853 | 4.83 ± 2.814 | 4.02 ± 2.477 |
| Day 7 Post dose | 6.19 ± 4.013 | 5.63 ± 3.562 | 4.92 ± 2.390 | 5.08 ± 2.849 | 6.41 ± 3.205 | 6.04 ± 4.109 | 4.54 ± 2.349 |
| Day 8 Post dose | 7.19 ± 4.489 | 3.21 ± 2.797 | 5.19 ± 3.646 | 3.70 ± 2.163 | 5.81 ± 3.391 | 4.40 ± 2.569 | 5.14 ± 3.359 |
| Day 9 Post dose | 5.11 ± 3.462 | 3.50 ± 1.780 | 4.20 ± 2.440 | 2.80 ± 1.859 | 5.63 ± 2.970 | 5.25 ± 2.478 | 5.39 ± 6.279 |
| Day 10 Post dose | 3.43 ± 2.992 | 3.17 ± 1.693 | 3.07 ± 2.110 | 2.70 ± 1.884 | 3.82 ± 1.647 | 2.67 ± 1.252 | 2.81 ± 1.731 |
| Day 11 Postdose | 3.57 ± 2.589 | 3.30 ± 3.054 | 1.50 ± 1.258 | 2.69 ± 2.086 | 3.59 ± 2.782 | 2.58 ± 1.530 | 2.50 ± 2.799 |
| Day 12 Post dose | 3.07 ± 2.263 | 3.30 ± 2.864 | 1.42 ± 1.068 | 1.81 ± 1.438 | 3.14 ± 2.521 | 2.58 ± 1.715 | 3.58 ± 4.364 |
| Day 13 Post dose | 4.07 ± 2.335 | 3.20 ± 3.883 | 2.58 ± 1.594 | 2.13 ± 1.847 | 1.71 ± 1.035 | 2.50 ± 1.549 | 2.58 ± 3.247 |
| Day 14 Post dose | 3.43 ± 1.988 | 2.70 ± 1.924 | 1.92 ± 1.201 | 1.21 ± 1.468 | 2.33 ± 1.366 | 3.00 ± 1.897 | 3.33 ± 3.204 |
Short Opiate Withdrawal Scale (SOWS)-Gossop: The SOWs scale is a validated 10-item patient-reported scale designed to measure the symptoms of withdrawal in subjects who are dependent on opioids.5 Each of the 10 items represents a symptom: "feeling sick," "stomach cramps," "muscle spasms/twitching," "feeling of coldness," "heart pounding," "muscular tension," "aches and pains," "yawning," "runny eyes," and "insomnia/problems sleeping." Scores on the SOWS-Gossop can range from 0 to 30, with higher scores indicating greater severity of withdrawal symptoms.
| score on a scale | 30 Micrograms | 60 Micrograms | 90 Micrograms | 120 Micrograms | 180 Micrograms | 240 Micrograms | Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Baseline, Pre-Dose, Day 6 | 3.59 ± 3.242 | 5.18 ± 3.861 | 5.95 ± 5.454 | 4.74 ± 4.641 | 4.95 ± 4.433 | 6.53 ± 7.376 | 6.21 ± 6.934 |
| Day 6 Postdose | 3.35 ± 3.071 | 7.13 ± 6.617 | 5.88 ± 3.916 | 5.79 ± 4.388 | 6.81 ± 5.815 | 8.50 ± 4.935 | 6.58 ± 6.780 |
| Day 7 Postdose | 6.73 ± 5.426 | 8.83 ± 6.959 | 7.39 ± 4.513 | 8.42 ± 6.380 | 11.53 ± 7.702 | 10.63 ± 9.670 | 7.54 ± 5.458 |
| Day 8 Postdose | 8.65 ± 7.967 | 4.86 ± 4.616 | 7.63 ± 5.614 | 6.85 ± 5.991 | 9.31 ± 7.765 | 10.15 ± 8.267 | 7.92 ± 6.828 |
| Day 9 Postdose | 6.11 ± 3.361 | 4.14 ± 2.428 | 5.65 ± 4.404 | 4.95 ± 5.325 | 8.21 ± 4.398 | 9.00 ± 7.521 | 7.06 ± 9.318 |
| Day 10 Postdose | 4.79 ± 4.030 | 3.33 ± 2.206 | 4.57 ± 4.457 | 3.50 ± 5.217 | 6.59 ± 3.740 | 5.08 ± 2.178 | 3.06 ± 3.076 |
| Day 11 Postdose | 2.79 ± 2.464 | 2.20 ± 2.414 | 3.00 ± 3.651 | 1.94 ± 2.195 | 5.18 ± 5.139 | 3.42 ± 2.223 | 3.50 ± 6.110 |
| Day 12 Postdose | 4.00 ± 4.252 | 2.20 ± 2.168 | 2.00 ± 2.387 | 2.19 ± 3.294 | 4.77 ± 4.967 | 3.67 ± 2.696 | 4.58 ± 6.953 |
| Day 13 Postdose | 3.93 ± 2.775 | 4.70 ± 7.068 | 2.08 ± 1.882 | 3.31 ± 3.891 | 2.21 ± 1.542 | 2.50 ± 1.049 | 3.25 ± 5.760 |
| Day 14 Postdose | 2.43 ± 2.637 | 2.40 ± 3.362 | 1.67 ± 2.251 | 1.71 ± 2.270 | 1.67 ± 2.338 | 1.08 ± 1.686 | 2.92 ± 6.216 |
Time to drop-out during double-blind treatment phase after discontinuation of opioid maintenance Phase.
| Days | 30 Micrograms | 60 Micrograms | 90 Micrograms | 120 Micrograms | 180 Micrograms | 240 Micrograms | Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Time to Drop-out After Discontinuation of Opioid Maintenance Phase | 3.1 (0.7 to NA) | 1.5 (0.00 to NA) | 3.1 (2.2 to 6.0) | 5.1 (1.1 to NA) | 6.1 (2.1 to NA) | 3.5 (1.0 to NA) | 2.0 (0.7 to 5.1) |
Number and Percentage of Subject Drop-out after Discontinuation of Opioid Maintenance Phase Within Each Treatment Group Between Days 6-14.
| Participants | 30 Micrograms | 60 Micrograms | 90 Micrograms | 120 Micrograms | 180 Micrograms | 240 Micrograms | Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Day 6 | 3 | 4 | 3 | 3 | 3 | 2 | 7 |
| Day 7 | 1 | 5 | 2 | 5 | 2 | 4 | 4 |
| Day 8 | 3 | 0 | 4 | 1 | 4 | 1 | 4 |
| Day 9 | 3 | 0 | 5 | 0 | 1 | 1 | 2 |
| Day 10 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Day 11 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Day 12 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Day 13 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Day 14 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Overall Agitation-Calmness Evaluation Scale (ACES): The ACES scale is a single-item measure rating overall agitation and sedation, ranging from 1 (marked agitation) to 9 (unarousable). This outcome measures the total ACES total score over time at 2 hours, post-first dose.
| units on a scale | 30 Micrograms | 60 Micrograms | 90 Micrograms | 120 Micrograms | 180 Micrograms | 240 Micrograms | Pooled Placebo |
|---|---|---|---|---|---|---|---|
| Day 6, Post-Dose | 4.6 ± 1.27 | 3.4 ± 1.71 | 4.4 ± 1.35 | 4.9 ± 1.31 | 4.7 ± 1.35 | 4.9 ± 1.73 | 4.3 ± 1.40 |
| Day 7, Post-Dose | 4.3 ± 0.95 | 3.6 ± 1.83 | 3.8 ± 1.29 | 3.9 ± 0.76 | 4.1 ± 1.48 | 4.4 ± 1.73 | 4.1 ± 0.86 |
| Day 8, Post-Dose | 3.8 ± 1.17 | 4.1 ± 1.07 | 4.0 ± 1.26 | 4.6 ± 1.43 | 4.2 ± 1.17 | 5.0 ± 1.83 | 4.1 ± 0.83 |
| Day 9, Post-Dose | 3.0 ± 0.87 | 4.1 ± 1.46 | 3.7 ± 0.67 | 4.5 ± 1.18 | 3.5 ± 0.80 | 4.7 ± 2.06 | 3.8 ± 0.46 |
| Day 10, Post-Dose | 4.1 ± 1.77 | 3.8 ± 0.98 | 4.1 ± 0.38 | 4.3 ± 1.06 | 4.3 ± 1.01 | 4.3 ± 1.37 | 4.4 ± 0.92 |
| Day 11, Post-Dose | 4.7 ± 1.50 | 4.0 ± 0.71 | 4.1 ± 0.38 | 4.1 ± 0.64 | 3.9 ± 0.94 | 4.2 ± 0.41 | 4.6 ± 1.13 |
| Day 12, Post-Dose | 4.3 ± 0.76 | 4.4 ± 1.4 | 4.7 ± 1.21 | 4.0 ± 0.00 | 4.1 ± 0.83 | 4.8 ± 1.33 | 4.0 ± 1.10 |
Collected over 9 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 30 Micrograms | 0/17 (0%) | 0/17 (0%) | 1/17 (5.9%) |
| 60 Micrograms | 0/17 (0%) | 0/17 (0%) | 5/17 (29.4%) |
| 90 Micrograms | 0/21 (0%) | 0/21 (0%) | 2/21 (9.5%) |
| 120 Micrograms | 0/19 (0%) | 0/19 (0%) | 4/19 (21.1%) |
| 180 Micrograms | 0/21 (0%) | 0/21 (0%) | 8/21 (38.1%) |
| 240 Micrograms | 0/15 (0%) | 0/15 (0%) | 9/15 (60%) |
| Pooled Placebo | 0/25 (0%) | 0/25 (0%) | 5/25 (20%) |
| Event | 30 Micrograms | 60 Micrograms | 90 Micrograms | 120 Micrograms | 180 Micrograms | 240 Micrograms | Pooled Placebo |
|---|---|---|---|---|---|---|---|
| SomnolenceNervous system disorders | 0/17 | 0/17 | 0/21 | 0/19 | 2/21 | 7/15 | 0/25 |
| HypotensionVascular disorders | 0/17 | 1/17 | 0/21 | 0/19 | 0/21 | 5/15 | 0/25 |
| Orthostatic HypotensionVascular disorders | 0/17 | 0/17 | 0/21 | 0/19 | 2/21 | 4/15 | 0/25 |
| VomitingGastrointestinal disorders | 0/17 | 1/17 | 0/21 | 1/19 | 1/21 | 3/15 | 0/25 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/17 | 0/17 | 0/21 | 1/19 | 3/21 | 0/15 | 1/25 |
| DiarrhoeaGastrointestinal disorders | 1/17 | 2/17 | 0/21 | 1/19 | 0/21 | 1/15 | 3/25 |
| AnxietyPsychiatric disorders | 0/17 | 2/17 | 0/21 | 0/19 | 1/21 | 0/15 | 0/25 |
| IrritabilityPsychiatric disorders | 0/17 | 2/17 | 0/21 | 0/19 | 0/21 | 0/15 | 0/25 |
| NauseaGastrointestinal disorders | 0/17 | 1/17 | 1/21 | 1/19 | 2/21 | 1/15 | 1/25 |
| BradycardiaCardiac disorders | 0/17 | 0/17 | 0/21 | 0/19 | 0/21 | 1/15 | 0/25 |
| Age, Continuous(years) | Cohort 1- 30 Micrograms | Cohort 2- 60 Micrograms | Cohort 3- 90 Micrograms | Cohort 4- 120 Micrograms | Cohort 5- 180 Micrograms | Cohort 6- 240 Micrograms | Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 41.6 ± 13.88 | 45.5 ± 12.56 | 39.3 ± 9.64 | 41.3 ± 9.55 | 42.9 ± 9.57 | 42.0 ± 11.86 | 42.1 ± 10.97 | 42.0 ± 10.99 |
| Sex: Female, Male(Participants) | Cohort 1- 30 Micrograms | Cohort 2- 60 Micrograms | Cohort 3- 90 Micrograms | Cohort 4- 120 Micrograms | Cohort 5- 180 Micrograms | Cohort 6- 240 Micrograms | Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 6 | 8 | 2 | 4 | 6 | 4 | 6 | 36 |
| Male | 11 | 9 | 19 | 15 | 15 | 11 | 19 | 99 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1- 30 Micrograms | Cohort 2- 60 Micrograms | Cohort 3- 90 Micrograms | Cohort 4- 120 Micrograms | Cohort 5- 180 Micrograms | Cohort 6- 240 Micrograms | Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 5 | 2 | 4 | 4 | 2 | 18 |
| Not Hispanic or Latino | 16 | 17 | 16 | 17 | 17 | 11 | 23 | 117 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1- 30 Micrograms | Cohort 2- 60 Micrograms | Cohort 3- 90 Micrograms | Cohort 4- 120 Micrograms | Cohort 5- 180 Micrograms | Cohort 6- 240 Micrograms | Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 10 | 4 | 6 | 7 | 5 | 9 | 48 |
| White | 10 | 7 | 16 | 12 | 13 | 10 | 16 | 84 |
| More than one race | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Height(cm) | Cohort 1- 30 Micrograms | Cohort 2- 60 Micrograms | Cohort 3- 90 Micrograms | Cohort 4- 120 Micrograms | Cohort 5- 180 Micrograms | Cohort 6- 240 Micrograms | Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 170.32 ± 6.933 | 170.14 ± 7.255 | 176.46 ± 10.176 | 171.57 ± 10.942 | 172.25 ± 10.349 | 174.17 ± 7.998 | 174.42 ± 9.220 | 172.92 ± 9.283 |
| Weight(kg) | Cohort 1- 30 Micrograms | Cohort 2- 60 Micrograms | Cohort 3- 90 Micrograms | Cohort 4- 120 Micrograms | Cohort 5- 180 Micrograms | Cohort 6- 240 Micrograms | Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 71.22 ± 10.604 | 66.38 ± 10.159 | 78.05 ± 13.827 | 82.04 ± 17.999 | 83.65 ± 26.189 | 83.51 ± 21.313 | 79.23 ± 21.480 | 77.98 ± 19.085 |
| Body Mass Index(kg/m^2) | Cohort 1- 30 Micrograms | Cohort 2- 60 Micrograms | Cohort 3- 90 Micrograms | Cohort 4- 120 Micrograms | Cohort 5- 180 Micrograms | Cohort 6- 240 Micrograms | Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 24.65 ± 4.135 | 22.95 ± 3.217 | 25.05 ± 3.824 | 28.16 ± 7.856 | 28.05 ± 8.248 | 27.47 ± 6.589 | 26.21 ± 7.721 | 26.12 ± 6.498 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — The Study Protocol and Statistical Analysis Plan (SAP) will be shared. Individual data is summarized by treatment group.
Ran from Jun 2020 to primary completion in Feb 2021, 8 months.
Results were first posted in Oct 2023, 2 years 8 months after primary completion.
Of 14 phase 1/2 interventional studies under Opioid-Related Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
BioXcel Therapeutics Inc